Mallinckrodt announced a $1.6 billion opioid settlement that will put the company’s generics business into bankruptcy.
A print advertisement of Alkermes Plc’s addiction treatment Vivitrol is false or misleading as the ad omits important risk information associated with the drug’s use, the Food and Drug Administration said in a warning letter to the company.
Dublin, Ireland-based Alkermes is acquiring Boston-based Rodin Therapeutics for $100 million up front and up to $850 million in milestone payments.
For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.
Baxter International Inc. was named in a complaint for improperly marketing opioid drugs and revealed an internal probe into the medical supplier’s accounting, sending the company’s shares down.
A federal appeals court rejected a bid by eight drug retailers and distributors to disqualify the judge overseeing nationwide opioid litigation after they claimed his rulings, public statements and efforts to encourage settlements created an appearance of bias.
Eight drug companies urged a federal appeals court to disqualify the judge overseeing nationwide opioid litigation, in a last-ditch effort to avoid having him preside over a landmark trial.
Teva Pharmaceutical Industries reported a smaller-than-expected drop in second-quarter 2019 profit and said the chief financial officer was leaving the company.
Eight months after announcing a plan to spin off the company’s generics business into a standalone company, Mallinckrodt Pharmaceuticals suspended that plan due to current market conditions and ongoing litigation over opioid sales.
Pfizer announced that the company’s Phase III RESET clinical trial evaluating rivipansel in sickle cell disease (SCD) failed to meet the study’s primary and key secondary efficacy endpoints.